	US 11,987,580 B2
	Bicyclic inhibitors of histone deacetylase
Nathan Oliver Fuller, Arlington, MA (US); and John A. Lowe, III, Stonington, CT (US)
Assigned to Alkermes, Inc., Waltham, MA (US)
Filed by Alkermes, Inc., Waltham, MA (US)
Filed on Dec. 22, 2021, as Appl. No. 17/559,488.
Application 17/559,488 is a continuation of application No. 17/007,151, filed on Aug. 31, 2020, granted, now 11,225,479, issued on Jan. 18, 2022.
Application 17/007,151 is a continuation of application No. 16/477,466, granted, now 10,793,567, issued on Oct. 6, 2020, previously published as PCT/US2018/013262, filed on Jan. 11, 2018.
Claims priority of provisional application 62/555,298, filed on Sep. 7, 2017.
Claims priority of provisional application 62/445,022, filed on Jan. 11, 2017.
Prior Publication US 2022/0340560 A1, Oct. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 31/437 (2006.01); A61P 25/28 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)

CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 31/519 (2013.01); A61P 25/28 (2018.01); C07D 487/04 (2013.01)]

17 Claims

1. A method of treating Alzheimer's disease, Huntington's disease, fronto-temporal lobar degeneration, Friedreich's ataxia, post-traumatic stress disorder, Parkinson's disease, Parkinson's disease dementia, substance dependence recovery, memory or cognitive function disorder or impairment, neurological disorder with synaptic pathology, disorder of learning distinction, psychiatric disorders, cognitive function or impairment associated with Alzheimer's disease, Lewy body dementia, schizophrenia, Rubinstein Taybi syndrome, Rett Syndrome, Fragile X, multiple sclerosis, age associated memory impairment, age related cognitive decline, and social, cognitive and learning disorders associated with autism in a subject in need thereof, comprising administering to the subject an effective amount of a compound having the Formula:

or a pharmaceutically acceptable salt thereof.